CTI Life Sciences Fund L.P.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

Find Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare inflammatory and fibrotic diseases affecting the airways, liver, and gastrointestinal systems. Founded in 2020 and headquartered in Saint-Laurent, Canada, the company specializes in creating G protein-coupled receptor (GPCR) allosteric modulators and employs a peptide discovery engine to design peptide-based therapies. These therapies target transmembrane domains of receptors that play crucial roles in various biological processes, facilitating the development of next-generation treatments for autoimmune conditions. By leveraging advanced technology and research capabilities, Find Therapeutics aims to address unmet medical needs in the field of inflammatory diseases.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

DalCor Pharmaceuticals, established in 2015, is a biopharmaceutical company specializing in precision medicine for cardiovascular diseases. Headquartered in Sarasota, Florida, with additional offices in Montreal, Zug, and Leatherhead, the company develops and commercializes targeted treatments based on patients' genetic profiles. DalCor's lead product, dalcetrapib, a cholesterol ester transfer protein inhibitor, is designed to reduce cardiovascular events in patients with a specific ADCY9 genetic profile, as demonstrated in a pharmacogenomics analysis of the dal-Outcomes study. The company holds a worldwide exclusive license for dalcetrapib and the ADCY9 genetic marker from Roche.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

Phenomic AI Inc. is a biotechnology company based in Toronto, Canada, focused on accelerating drug discovery and developing therapies for cancer. Founded in 2017, Phenomic AI has created an innovative drug discovery platform that leverages artificial intelligence and computer vision to analyze phenotypic assays. This platform enables the examination of complex disease models, including high-content co-culture and three-dimensional assays, allowing pharmaceutical companies to discover and optimize therapeutics more efficiently. By specializing in targeting tumor stroma, Phenomic AI aims to enhance the drug development process, making it easier for researchers to identify effective medicines.

Find Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare inflammatory and fibrotic diseases affecting the airways, liver, and gastrointestinal systems. Founded in 2020 and headquartered in Saint-Laurent, Canada, the company specializes in creating G protein-coupled receptor (GPCR) allosteric modulators and employs a peptide discovery engine to design peptide-based therapies. These therapies target transmembrane domains of receptors that play crucial roles in various biological processes, facilitating the development of next-generation treatments for autoimmune conditions. By leveraging advanced technology and research capabilities, Find Therapeutics aims to address unmet medical needs in the field of inflammatory diseases.

Phenomic AI Inc. is a biotechnology company based in Toronto, Canada, focused on accelerating drug discovery and developing therapies for cancer. Founded in 2017, Phenomic AI has created an innovative drug discovery platform that leverages artificial intelligence and computer vision to analyze phenotypic assays. This platform enables the examination of complex disease models, including high-content co-culture and three-dimensional assays, allowing pharmaceutical companies to discover and optimize therapeutics more efficiently. By specializing in targeting tumor stroma, Phenomic AI aims to enhance the drug development process, making it easier for researchers to identify effective medicines.

Vaxcyte, Inc. is a preclinical-stage biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. Headquartered in Foster City, California, Vaxcyte's lead candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company is also advancing VAX-XP, which aims to address emerging strains of pneumococcal disease and antibiotic resistance. Additionally, Vaxcyte is developing VAX-A1, a conjugate vaccine for Group A Streptococcus, and VAX-PG, a novel therapeutic vaccine targeting periodontal disease. Utilizing a proprietary cell-free protein synthesis platform, Vaxcyte designs and produces the essential components of vaccines, enhancing their efficacy compared to traditional technologies. Founded in 2013 and originally named SutroVax, Vaxcyte rebranded in May 2020 to reflect its commitment to improving global health through superior vaccine development.

Phenomic AI Inc. is a biotechnology company based in Toronto, Canada, focused on accelerating drug discovery and developing therapies for cancer. Founded in 2017, Phenomic AI has created an innovative drug discovery platform that leverages artificial intelligence and computer vision to analyze phenotypic assays. This platform enables the examination of complex disease models, including high-content co-culture and three-dimensional assays, allowing pharmaceutical companies to discover and optimize therapeutics more efficiently. By specializing in targeting tumor stroma, Phenomic AI aims to enhance the drug development process, making it easier for researchers to identify effective medicines.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

PreciThera, Inc. is a biotechnology company based in Montreal, Canada, founded in 2016. It specializes in developing biological therapeutics for rare bone diseases, particularly targeting heterogeneous genetic disorders that manifest as bone dysfunction. By leveraging computational technology and a comprehensive understanding of disease pathology, PreciThera aims to create precision medicines that address both skeletal and extraskeletal symptoms associated with these conditions. Its targeted therapeutic strategies seek to enhance treatment options for patients, focusing on traditional protein replacement therapies to improve overall health outcomes.

PHEMI Systems Corporation specializes in developing a comprehensive privacy, security, governance, and data management system optimized for Microsoft Azure. Founded in 2013 and based in Vancouver, Canada, the company focuses on the healthcare sector, offering the PHEMI Data Privacy Manager. This cloud-based platform addresses the critical need for healthcare organizations to secure, manage, and control access to sensitive information while ensuring compliance with privacy regulations. Built on a privacy-by-design architecture, PHEMI’s software facilitates data sharing and integrates seamlessly with numerous data sources, as well as popular data science and business analysis tools. The platform is designed to scale according to the organization's size and offers a flexible usage-based pricing model.

Vaxcyte, Inc. is a preclinical-stage biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. Headquartered in Foster City, California, Vaxcyte's lead candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company is also advancing VAX-XP, which aims to address emerging strains of pneumococcal disease and antibiotic resistance. Additionally, Vaxcyte is developing VAX-A1, a conjugate vaccine for Group A Streptococcus, and VAX-PG, a novel therapeutic vaccine targeting periodontal disease. Utilizing a proprietary cell-free protein synthesis platform, Vaxcyte designs and produces the essential components of vaccines, enhancing their efficacy compared to traditional technologies. Founded in 2013 and originally named SutroVax, Vaxcyte rebranded in May 2020 to reflect its commitment to improving global health through superior vaccine development.

CellAegis Devices Inc. is a Toronto-based company that specializes in developing, manufacturing, and commercializing medical devices. Its flagship product, the autoRIC Device, delivers remote ischemic conditioning (RIC) in a non-invasive manner to protect the heart during heart attacks and other cardiovascular procedures. This automated device is designed for use in various settings, including hospitals, ambulances, and at home. Additionally, the company provides the CRICtrac mobile app, which enables clinicians to offer patients self-administered chronic RIC therapy at home. CellAegis Devices serves a broad market across Canada and Europe, focusing on enhancing patient care through innovative medical technology.

Ilkos Therapeutic is a company focused on developing an oral compound specifically designed to treat venous lower limb ulcers, a condition primarily affecting older adults. The firm capitalizes on Quebec's strong life sciences sector, leveraging its quality research and development infrastructure alongside available capital to advance new therapeutic solutions. By providing an effective treatment option for this challenging medical issue, Ilkos Therapeutic aims to enhance patient care and improve outcomes for those suffering from venous lower limb ulcers.

IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

DalCor Pharmaceuticals, established in 2015, is a biopharmaceutical company specializing in precision medicine for cardiovascular diseases. Headquartered in Sarasota, Florida, with additional offices in Montreal, Zug, and Leatherhead, the company develops and commercializes targeted treatments based on patients' genetic profiles. DalCor's lead product, dalcetrapib, a cholesterol ester transfer protein inhibitor, is designed to reduce cardiovascular events in patients with a specific ADCY9 genetic profile, as demonstrated in a pharmacogenomics analysis of the dal-Outcomes study. The company holds a worldwide exclusive license for dalcetrapib and the ADCY9 genetic marker from Roche.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

PHEMI Systems Corporation specializes in developing a comprehensive privacy, security, governance, and data management system optimized for Microsoft Azure. Founded in 2013 and based in Vancouver, Canada, the company focuses on the healthcare sector, offering the PHEMI Data Privacy Manager. This cloud-based platform addresses the critical need for healthcare organizations to secure, manage, and control access to sensitive information while ensuring compliance with privacy regulations. Built on a privacy-by-design architecture, PHEMI’s software facilitates data sharing and integrates seamlessly with numerous data sources, as well as popular data science and business analysis tools. The platform is designed to scale according to the organization's size and offers a flexible usage-based pricing model.

Vaxcyte, Inc. is a preclinical-stage biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. Headquartered in Foster City, California, Vaxcyte's lead candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company is also advancing VAX-XP, which aims to address emerging strains of pneumococcal disease and antibiotic resistance. Additionally, Vaxcyte is developing VAX-A1, a conjugate vaccine for Group A Streptococcus, and VAX-PG, a novel therapeutic vaccine targeting periodontal disease. Utilizing a proprietary cell-free protein synthesis platform, Vaxcyte designs and produces the essential components of vaccines, enhancing their efficacy compared to traditional technologies. Founded in 2013 and originally named SutroVax, Vaxcyte rebranded in May 2020 to reflect its commitment to improving global health through superior vaccine development.

Xagenic Inc., based in Toronto, Canada, specializes in developing molecular diagnostics technology for rapid, decentralized testing. Their aim is to empower clinicians with on-demand, near-patient molecular testing capabilities, enabling timely treatment decisions and improving patient care while reducing healthcare costs. Xagenic's platform detects nucleic acids from clinical samples without the need for enzymes, delivering results in just 20 minutes. This allows for widespread diagnostic testing outside of traditional clinical laboratories, initially focusing on infectious disease tests.

XTuit Pharmaceuticals, Inc., established in 2011 and headquartered in Waltham, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. The company focuses on creating pharmaceutical preparations for diagnosing and treating oncological, tumor, and inflammatory diseases by pursuing novel approaches that target the tumor microenvironment. Its drug development pipeline and clinical biomarker platform aim to create drugs that inhibit extracellular matrix synthesis and stabilization, and silence activated stromal cells through pleiotropic mechanisms.

Profound Medical Corp. is a medical technology company based in Mississauga, Canada, specializing in the development of innovative, incision-free therapeutic systems for the image-guided ablation of diseased tissue. The company’s flagship product, the TULSA-PRO system, integrates real-time magnetic resonance imaging with robotically driven thermal ultrasound to precisely ablate prostate tissue. Additionally, Profound Medical offers the Sonalleve platform, which is designed for treating uterine fibroids and managing palliative pain associated with bone metastases. By leveraging existing MRI infrastructure, the company aims to provide customizable and non-invasive treatment options that address the unmet needs of patients and clinicians. Profound Medical is committed to enhancing the standard of care through its advanced technologies and has established a co-development agreement with GE Healthcare to broaden access to its TULSA-PRO system.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

GLyPharma Therapeutics, founded in Montréal in August 2012, focuses on developing innovative therapies for rare gastrointestinal diseases, including short bowel syndrome. The company has established a strategic partnership with Ferring Pharmaceuticals, a European firm specializing in peptide development, along with FONDS de solidarité FTQ and CTI Life Sciences Fund. GLyPharma's lead compound, FE 203799, is a long-acting Glucagon-Like Peptide-2 (GLP-2) receptor agonist that exhibits intestine-trophic and protective properties. This compound is being developed under an exclusive worldwide license from Ferring for its potential use in supportive care for oncology patients, specifically aimed at mitigating chemotherapy-induced intestinal mucositis.

Xagenic Inc., based in Toronto, Canada, specializes in developing molecular diagnostics technology for rapid, decentralized testing. Their aim is to empower clinicians with on-demand, near-patient molecular testing capabilities, enabling timely treatment decisions and improving patient care while reducing healthcare costs. Xagenic's platform detects nucleic acids from clinical samples without the need for enzymes, delivering results in just 20 minutes. This allows for widespread diagnostic testing outside of traditional clinical laboratories, initially focusing on infectious disease tests.

Medicago Inc. is a biotechnology company headquartered in Quebec City, Canada, specializing in the research, development, and commercialization of vaccines. The company employs proprietary plant-based manufacturing and virus-like particle (VLP) technologies to create innovative vaccines and therapeutics for infectious diseases. Its notable product candidates include a VLP vaccine for the H5N1 pandemic influenza, which has successfully completed Phase I clinical trials, as well as an H1N1 VLP vaccine aimed at the Influenza A/California/04/09 virus and various seasonal influenza vaccines. Medicago has established collaboration agreements with organizations such as Viridis S.A. and Genopole biopark for the production of pandemic and seasonal influenza vaccines, alongside a partnership with Philip Morris International for developing a therapeutic protein with a human-compatible glycosylation pattern. Founded in 1997, Medicago is dedicated to addressing emerging public health challenges through its advanced vaccine technologies.

NeurAxon, Inc. is a Canadian company focused on discovering and developing therapeutics for pain management by targeting neuronal nitric oxide synthase. Founded in 2004 and headquartered in Toronto, NeurAxon is advancing a pipeline of oral products aimed at treating various pain conditions, including acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. By utilizing selective inhibitors of nitric oxide synthase, the company seeks to provide effective solutions for individuals suffering from these conditions.

Somnus Therapeutics, Inc. is a drug development company focused on creating therapeutics for patients suffering from insomnia. Founded in 2007 and based in Bedminster, New Jersey, the company specializes in products designed to prevent midnight awakenings, allowing patients to achieve a more restful sleep without experiencing next-day hangovers. By addressing these specific needs, Somnus Therapeutics aims to improve treatment outcomes and enhance the quality of life for individuals affected by insomnia.

Chlorion Pharma is a start-up biotechnology company focused on developing innovative therapeutics for the treatment of pain and epilepsy. The company's approach targets neuronal hyperactivity by correcting aberrant chloride homeostasis, aiming to provide effective solutions for patients suffering from neuropathic diseases. Through its research and development efforts, Chlorion Pharma seeks to address unmet medical needs in the field of neurology, offering the potential for improved therapeutic outcomes for individuals affected by these conditions.

Enobia Pharma is a biotechnology company focused on developing innovative therapies for serious genetic bone disorders that currently lack approved treatment options. The company specializes in addressing conditions such as hypophosphatasia (HPP), a rare inherited disorder that affects bone mineralization and can lead to severe complications. By concentrating on these unmet medical needs, Enobia aims to provide effective solutions that improve patient outcomes and quality of life for individuals suffering from these challenging conditions.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.